Возможности улучшения контроля артериальной гипертонии путем выявления проблем взаимодействия «врач — пациент» и выбора рациональной фармакотерапии
Диссертация
Актуальность проблемы. Артериальная гипертония (АГ) является основным фактором сердечно-сосудистого риска во всем мире: 62% цереброваскулярных заболеваний и 49% случаев ишемической болезни сердца (ИБС) связаны с незначительным повышением артериального давления (АД) свыше 115 мм рт. ст. (Menard J. 2006). Показатели эффективного контроля АГ, даже в развитых европейских странах, не превышают 30… Читать ещё >
Список литературы
- Автандилов А.Г. Артериальная гипертензия у подростков мужского пола. -М.: РМАПО, 1997. -286 с.
- Виленский B.C. Современная тактика борьбы с инсультом. -М: 2005. -46 с.
- Гринштейн Ю. И, Шабалин В. В. Доклиническая диагностика поражения почек при гипертонической болезни//Кардиоваскулярная терапия и профилактика. -2003.-2 (4) -С. 50−53.
- Кобалава Ж.Д., Виллевальде C.B. Диуретики краеугольный камень современной антигипертензивной терапии//Артериальная гипертензия. -2006.-11,(4) -С. 217−225.
- Кобалава Ж.Д., Гудков K.M. Эволюция представлений о стресс-индуцированной артериальной гипертонии и применении антагонистов рецепторов ангиотензина 11//Кардиоваскулярная терапия и профилактика.-2002.-№ 1-С. 4−15.
- Люсов В. А, Евсиков Е. М, Ошнокова A.A. и соавт. Современные данные о клинике и патогенезе артериальной гипертензии тяжелого и злокачественного течения// Российский Кардиологический Журнал.-2005.-4(54) -С 6−18.
- Маколкин В. И. Применение современных бета-адреноблокаторов приартериальной гипертонии у больных с метаболическим синдромом// Артериальная гипертензия. -2005.-11(3)-С. 149−154.
- Медик В.А. Заболеваемость населения: история, современное состояние и методология изучения. -М: Медицина, 2003.-68 с.
- Мясников А.Л. Гипертоническая болезнь и атеросклероз. -М: Медицина, 1965.-312 с.
- Моисеев В. С, Кобалава Ж. Д. АРГУС. АРтериальная гипертония У лиц Старших возрастных групп. -М: Медицинское информационное агенство, 2002. -448 с.
- Моисеев В. С, Кобалава Ж. Д. Систолическое давление ключевой показатель диагностики, контроля и прогнозирования риска артериальной гипертонии. Возможности блокады рецепторов ангиотензина П//Клиничекая фармакология и терапия.-2000.-№ 5 -С. 1723.
- Оганов Р. Г, Калинина А. М, Поздняков Ю. М. Профилактическая кардиология. -М: МИД «Синергия», 2003. -389 с.
- Оганов Р. Г, Галкин В. А, Масленникова Г. Я. Артериальная гипертония -проблема поликлиническая//Терапевтический архив.- 2006.- № 1-С. 6−9.
- Основы законодательства Российской Федерации об охране здоровья граждан от 22 июля 1993 г. N5487−1 (с изменениями от 20 декабря 1999 г.)
- Профилактика диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр)//Кардиоваскулярная терапия и профилактика Приложение.-2004. -№ 6 -С. 3−19.
- Рекомендации по профилактике, диагностике и лечению артериальной гипертензии.//Артериальная гипертензия (приложение).-2001. -№ 1 -С. 416.
- Фомин В. В, Моисеев С. В, Сагинова Е. А. Больной артериальной гипертонией, не приверженный лечению//Согш1шт МесНсит.-2006. -8(5) -С. 1164−1168.
- Фомин И.В., Мареев В. Ю., Фадеева И. П. и др. Истинная распространенность артериальной гипертонии и современное состояние гипотензивной терапии в Нижегородской области (данные регистра)//Кардиология. -2000. -№ 8 -34−36.
- Чазова И.Е., Бойцов С. А., Небиеридзе Д. В. Основные положения проекта второго пересмотра Рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии //Кардиоваскулярная терапия и профилактика.-2004.-№ 4 -С. 90−98.
- Чазов Е.И., Чазова И. Е. Руководство по артериальной гипертонии.-М: Медиа Медика, 2005. -734 с.
- Шальнова С. А, Деев А. Д, Оганов Р. Г, Шестов Д. Б. Роль систолического и диастолического АД для прогноза смертности от сердечно-сосудистых заболеваний/ЛСардиоваскулярная терапия и профилактика.-2002 -№ 1 -С. 10−15.
- Шальнова СА, Деев АД, Вихирова ОВ и др. Распространенность артериальной гипертонии в России: информированностиь, лечение, контроль/ЯТрофилактика заболевания и укрепление здоровья. -2001. -№ 2 -С. 3−7.
- Шальнова СА. Проблемы лечения артериальной гипертонии// Кардиоваскулярная терапия и профилактика. -2003. № 3 -С. 17−21.
- Широков Е.А. Коррекция артериальной гипертонии в современной профилактике инсультов//Русский Медицинский Журнал. -2006. 14(23) -С. 1692−1695.
- Aram V., Chobanian G.L., Bakris H.R., et al. Seventh Report of the Joint National" Committee on Prevention, Detection, Evaluation, and Treatment of
- High Blood Pressure/ZHypertension. -2003 -V.42 -P 1206−1252.
- Asmar R., Amah G., Crisan O., et al .//Eur. Heart J. -1999. -VI. -P. 3−8:
- Beevers D.G., Lip GYH. Does non-malignant essential hypertension cause renal damage? A clinician’s view//J. Hum. Hypertens. -1996. -V.10 -P. 695.
- Baguet J.F., Robitail S., Boyer L., et al. A Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure//Am. J. Cardiovasc. Drugs. -2005. -V. 5(2)-P. 131−140.
- Black H.R. The paradigm has shifted to systolic blood pressure// J. of Human Hypertension. -2004. -V. 18 -S3.
- Bobrie G., Chatallier G., Genes N., et al. Cardiovascular prognosis of «Masked Hypeertension» detected by Blood Pressure Self-mesurement in Elderly Treated Hypertensive Patients//JAMA. -2004. -V. 291 -P. 1342−1349.
- Borghi C., Dormi A., D’Addato S., et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study//J. Hypertens. -2004. -V. 22 -P. 1707−1716.
- Burt V.L., Whelton P., Roccella J.F., et al. Prevalens of Hypertensions in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1989−1981//Hypertension. -1995. -V. 25 -P. 305−313.
- Clause S.L., Hamilton R.A. Medicaid prescriber compliance with Joint National Committee VI Hypertension Treatment Guidelines//Ann. Pharmacother. -2002. -V. 36 -1505−1511.
- Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh Report of the Joint National' Committee' on prevention- detection, evaluation* and' treatment of high blood pressure/ZHypertens. -2003. -V. 42 -P. 1206−1252.
- Christopher J: O’Donnel, Ridken P.M., et al. Hypertension and Borderline Isolated Systolic Hypertension Increase Risk of Cardiovascular, Disease and Mortality in Male Physicians//Circulation. -1997. -V. 95 -P. 1132.
- Cuspidi C., Michev I., Lonati L., et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy//J. Hum. Hypertens. -2002.-V. 16-P. 699−703.
- D?Agostino R.B., Wolf P.A., Belanger A.J., Kannel W.B. Stroke risk profile: adjustment for antihypertensive medication: the Framingham Study//Stroke -1994. -V.25 -P. 40−43.
- Dahlof B., Devereux R.B., Kjeidsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol/ZLancet. -2002. -V. 359 -P. 995−1003.
- Dahlof B., Ekbom T., et al. Prognostic factors in the treatment of mild hypertension. The Management Committee of the Australian National Blood Pressure Study//Circulation. -1984. -V. 69. P. 668−676.
- Degli Esposti E., Di Martino M., Sturani A. Risk factors for uncontrolled hypertension in Italy//J. Hum. Hypertens. -2004. -V. 18 -P 207−213.
- Elser M. The sympathetic system and hypertension//Am. J. Hypertens. -2000. V. 13 -P. 99−105.
- Ezzaty M., Hoorn S.V., Rodgers A., et al. Estimates of global and regional potential health gains from reducing multiple major risk factors//Lancet. -2003. -V. 362(9380) P. 271−280.
- Ezzaty M., Lopez A.D., Rodgers A., et al. Selected- major risk factors and global and regional burden of disease/ZLancet. -2002. -V. 360(9343) -P. 1347−1360.
- Fletcher A., Amery A., Birkenhager W., et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly//J. Hipertens. -1991. -V. 9 -P. 2225−2230.
- Fodor G.J., Kotrec M., Bacskai K., et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central
- European study//J. Hypertens. -2005. -V. 23 -P. 1261−1266.
- Frohlich E.D. The necessity for recognition’and treatment of patients with «mild» hypertension//J. Am. Coll. Cardiol. -1999. -V. 34. -P. 1369−1377.
- Guibert R., Franco E.D., Choosing a definition of hypertension: impact on epidemiological estimates//.!. Hypertension. -1996. -V. 14(11) -P. 1275−1280.
- Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988−2000//JAMA. -2003. -V. 290. -P. 199−206.
- Hosie J., Wiklund I. Managing hypertension in general practice: can we do better?//J. Hum. Hypertens. -1995. V. 9. -S15-S18.
- Hughson W.G., Mann J.I., Garrod A. Intermittent claudication- prevalence and risk factors//BMJ. -1978. -V. 1 -P. 1379.
- Hansson L., Dahlof B., Ekbom T., et al. Key learnings from the STOP-Hypertension study: an update on the progress of the ongoing Swedish-, study of antihypertensive treatment in the elderly//Cardiovasc Drugs Therap. -1991. -V. 4 (Suppl 6)-P. 1253−1255.
- Iskedjian M., Einarson T.R., MacKeigan L.D., et al. Relationship betweendaily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis//Clin. Ther. -2002. -V. 24 -P. 302−16.
- Julius S., Krause L., Schork N., et al. Hyperkinetic borderline Hypertension in Tecumseh, Michigan//.!. Hyprtens. -1991. V. 9 -P. 77−84.
- Kannel W.B., Gordon Т., Schwartz M.J. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study//Am. J. Cardiol. -1971. -V. 27-P. 335−346.
- Kannel W.B. Elevated* systolic Blood pressure as a cardiovascular risk factor//Am. J. Cardiol. -2000. -V. 85 -P. 251−255.
- Kannel W.B., Schwartz M.J., McNamara P.M. Blood pressure and risk of coronary heart disease: the Framingham study//Dis. Chest. -1969. V. 56(1) -P. 43−52.
- Kaplan N.M. Hypertension in the population at large. In: Kaplan’s Clinical Hypertension, 8th edition. Kaplan N. M, Lieberman E, Neal W, et al. Philadelphia: Lippincott Williams & Wilkins- -2002.
- Kearney P.M., Whelton M., Reynolds K., et al. Worldwide prevalence of hypertension: a systematic review//J. Hypertens. -2004 -V. 22(1) -P. 11−19.
- Keith N.M., Wagener H.P., Barker N.W. Some different types of essential hypertension: their course and prognosis//Am. J. Med. Sci. -1939. -V. 196 -332.
- Keil J.E., Southerland S.E., Knapp R.G., et al Mortality rates and risk factors for coronary heart disease in black as compared with white men and women//New Engl. J. Med. -1993 -V. 329 -P. 73−78.
- Keil J.E., Southerland S.E., Hames C.G., et al. Coronary disease mortality and risk factors in black and white men. Results from the combined Charleston SC and Evans Country, Georgia, heart studies//Arch. Intern. Med. -1995.-V. 155-P. 1521−1527.
- Lacroix A., Assal J.F. Therapeutic Education of Patients. New approaches to chronic illness. -2003.
- Lenfant С. Гипертензия и ее последствия: состояние проблемы в
- MHpe//ApTepHajibHaHiranepTeH3HH. -2005. 11 (2) -C. 86−90.
- Lewington S., Clarke R., Qizilbash N., et alt Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies/ZLancet. -2002. -V. 360 V. 9349 -P. 1903−1913.
- Lewington S., et alt Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies/ZLancet.-2002 V. 360 -P. 1903−1913.
- Macedo M.E., Lima M.J., Silva A.O., et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study//!- Hypertens. -2005. V. 23-P. 1661−1666.
- MacMahon S. Blood pressure and the risks of cardiovascular disease. In: Swales JD editor. Textbook of hypertension. Oxford: Blackwell. -1994. -P 46.
- Macray J., Mensah G. The Atlas of Heart Disease and Stroke. World- Health 0rganization2004.
- Mancia G., Broun M., Castaigne A., et al. Outcomes with nifedipine GITS or co-amilozide in ¦ hipertensive diabetics and nondiabetics in Interventions as a Goal in Hypertension (INSIGHT)//Hypertension. -2003- -V. 41 -P. 431−436.
- Mancia G., De Backer G., Dominiczak A., et alt 2007 Guidelines for the management of Arterial Hypertension of the European Sotiety of Hypertension (ESH) and othe European Sotiety of Cardiology (ESG)//Hypertens. -2007. -V. 25 -P. 1105−1187.
- Manjunath G., Tighiouart I I., Ibrahim Hi, et alt Level ofkidney functiomas a risk factor for atherosclerotic cardiovascular outcomes in the community//J. Am. Coll. Cardiol. -2003. -V. 41 -P. 47−55.
- Medical research counsil working party. Medical research counsil trial to treatment of hypertension in older adults: principal results//BMJ. -1992. -V. 304-P. 405−412.
- Menard J., Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice?//J. Hum. Hypertens. -1995. -V. 9 -S19-S23.
- Moser M. Hypertension Treatment Guidelines: Is It Time for an Update//Journal of Clinical Hypertension. -2001. -V. 9(1) -P. 9−14.
- MRFIT Research Group. Mortality after 10.5 years for hypertensive participants in the Multiple Risk factor Intervention Trial//Circulation. -1990. -V. 82-P. 1616−1628.
- Murray C., Lopez A. The Global Burden of Disease. Cambridge, Harvard University Press. -1996.
- National Collaboration Center for Chronic Condition. Hypertension: management of hypertensionin adults in primary care: London Royal College of Phisicians. -2006.
- Neaton J.D., Grimm R.H., Prineas R.J., et al. Treatment of mild hypertension study: final results//JAMA. -1993. -V. 270 -P. 713−724.
- Paul K. Epidemiology and the Prevention of Hypertension//J. Clin. Hypertens. -2004. -V. 6 (11) -P. 636−642.
- Phillips S.J., Whisnant J.P. Hypertension and the brain. The national high blood pressure education program//Arch. Intern. Med. -1993 -V. 152 -P. 938.
- Psaty B.M., Furberg C.D., Kuller L.H., et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the-cardiovascular health study//Arch. Intern. Med. -1992. -V. 152 -P. 56−64.
- Psaty B.M., Lumley T., Furberg C.D., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis//JAMA. -2003. -V. 289-P. 2534−2544.
- Psaty B.M., Smith N.L., Siscovick D.C., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis//JAMA. -1997. V. 277 P. 739−745.
- Raine A.E. Hypertension and the kidney/ZBritish Medical Bulletin. -1994. -V. 50-P. 322−341.
- Report of the joint national committee on prevention detection and treatmentof high blood pressure (JNC VI)//Arch. Med. -1997 -V. 157 P. 2413.
- Ruilope L.M., Salvetti A., Jamerson K., et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study//! Am. Soc. Nephrol. -2001. -V. 12 -P. 2218−225.
- Ruilope L.M., van Veldhuisen D.J., Ritz E., et al. Renal function: the Cinderella of cardiovascular risk profile//J. Am. Coll. Cardiol. -2001. V. 38 -P. 1782−1787.
- Sagie A., Martin G.L., Levy D. The Natural Hystory of Borderline Isolated Systolic Hypertension//The New England Journal of Medicine -1993. -V. 329 (26) P. 1912−1917.
- Schroeder K., Fahey T., Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials//Arch. Intern. Med. -2004. V. 164 -P. 722−732.
- Schroeder K., Fahey T., Ebrahim S. Interventions for improving adherence to treatment in* patients with- high- bloods pressure' in ambulatory settings//Cochrane Database Syst Rev -2004. V. 2: CD004804.
- Sever P., Beevers D.G., Bulpitt C., et al. Management guidelines in essential hypertension: report of the* second working party of the British Hypertension Society//BMJ. -1993. -V. 306 -P. 983.
- Sever P. S., Dahof B. American College of Cardiology 2005 Scientific Sessions. -March 6−9, 2005. Orlando, FL.
- Shaper A.G., Phillips A.N., Pollock S.J., et al. Risk factors for stroke inmiddle-aged British men//BMJ. -1991. -V. 302 -P. 1111.
- Shultz J., Schmidt J., Rick W. The value of nifedipine in the treatment of hypertension, coronary heart disease and myocardial infarction (postinfarction therapy)//Current Medical Research and Opinion. -1996. -V. 13 (7). -P. 397−408.
- Spencer C. Hypertension, Epidemiology and Risk//Pharmaceutical Journal. -1999. -V. 263 -P. 280−283.
- Stamler J., Neaton J.D., Wentwort D.N. Blood pressure (systolic and diastolic) and risk of fatal coronaryheart disease//Hypertension. -1989. V. 13 (5 suppl.) —P. 12.
- Stroke prevention in atrial fibrillation study investigators. Patients at low risk of stroke during treatment with aspirin: Stroke prevention in atrial fibrillation III study//JAMA. -1998. -V. 279 -P. 1273.
- Stamler J., Stamler A., Neaton J.D. Blood pressure systolic and diastolic, and cardiovascular risk: U.S. population data//Arch. Intern. Med. -1993. -V. 153-P. 598−615.
- Staessen J.A., Wang J J.// Eur. Heart J. -1999. -V. 1 -P.3−8.
- The Atlas of Heart Disease and Stroke WHO. WHO site. Cardiovascular disease. -2007.
- The seventh report of the joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure//JAMA. -2003. -V. 289 (19)-P. 2560−2572.
- Wilson K., Gibson N., Willan A., Cook D., Effect of smoking on mortality after myocardial infarction: meta-analysis of cohort studies//Arch. Intern. Med. -2000. -V. 160 -P 939−934.
- World Health Organization, International Society of Hypertension Writing
- Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension//Journal of Hypertens. -2003. -V. 21 -P. 1983−1982.
- Wolf-Maier K., Cooper R.S., Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States/ZHypertension. -2004. -V. 43 -P. 10−17.
- Wetzels G.E., Nelemans P., Schouten J.S., Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review//! Hypertens. -2004. -V. 22 -P. 1849−1855.
- Veterans Affairs Cooperative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg//JAMA. -1967. -V. 202 -P. 1028−1034.
- Veterans Affairs Cooperative Study Group. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg//JAMA. -1970. -V. 213 -P. 1143−1052.
- Wing L.M., Reid C. M, Ryan P., et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in elderly//N. Engl. J. Med. -2003. -V. 348 -P. 583−592.
- World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization WHO/International society of Hypertension (ISH) statement on management of hypertension//Ji. Hypertens. -2003. -V. 21 -P. 1983−1992. '